What Nabla Bio does
Nabla Bio is a Cambridge, Massachusetts-based biotechnology company developing generative AI methods for de novo protein and antibody therapeutics design, combining computational modeling with large-scale, human-relevant experimental testing. The company’s stated goal is to make drug development “designable” by reducing trial-and-error, by training and refining its models on measurements produced in-house from mammalian and in vivo contexts.
At the platform level, Nabla describes Joint Atomic Model (JAM) as a multimodal generative modeling system that takes partial molecular context (for example, a disease target or epitope) and performs the rest of the design process via “autocomplete”-style generation. In Nabla’s account, JAM is paired with integrated experimental systems that generate thousands of protein designs, and measure binding, developability properties, and function in cellular and in vivo contexts, with the intent to eliminate iterative “lab-in-the-loop” screening. The company says JAM enables parallel de novo antibody design campaigns, epitope-precise binding-site specification, and generative design of multispecific antibody architectures.
Commercially, Nabla positions itself as a partner to pharmaceutical companies for early-stage discovery and protein therapeutics R&D. Public disclosures show multiple collaborations with large pharma, including a multi-year second collaboration with Takeda announced in October 2025, and earlier collaborations referenced in its Series A disclosures.
As of the information available from Nabla Bio’s website and public deal announcements, the company appears to remain privately held and venture-backed.